Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Inex, Alnylam form technology alliance

January 15, 2007 | A version of this story appeared in Volume 85, Issue 3

Inex Pharmaceuticals has granted Alnylam an exclusive license to liposomal delivery technology for RNAi therapeutics. In exchange, Inex will receive $8 million in cash or stock and $4 million in R&D funding over the next two years. Inex will manufacture any drugs that come out of the collaboration, using $5 million from Alnylam for any needed equipment. Inex will also receive exclusive access to Alnylam's intellectual property related to the development of immune stimulatory oligonucleotides that do not act on an RNAi pathway.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.